Medical Malpractice Leads: Volume Is Not the Constraint

A firm that has bought injury leads before arrives at medical malpractice with a set of habits that do not work here. Buy more, sign more, adjust the spend. That relationship is genuinely how most of the injury verticals behave, and it is why the advice about them is broadly interchangeable.

Medical malpractice does not behave that way, and the reason is specific rather than vague. In a motor vehicle case a firm can tell within one conversation whether there is something to pursue. In a malpractice case it frequently cannot tell until it has ordered the records and paid somebody qualified to read them. The qualification step has a real cost attached to it, and that cost is paid on cases the firm will decline.

Everything strange about buying leads in this vertical follows from that.

Why a bad outcome is not a case

Almost everyone who contacts a firm about malpractice has had something bad happen to them. That is not in dispute and it is not what is at issue. What has to be established is that the care fell below the accepted standard, and that the harm came from that failure rather than from the underlying illness, a known complication, or bad luck.

Those are three separate things, and the people calling have no way to tell them apart. Nor should they be expected to. But it means the raw enquiry pool in this vertical is dominated by people with a genuine grievance and no claim, and no amount of screening at the campaign stage fully fixes that, because the answer lives in a medical chart nobody has read yet.

A firm that has not internalised this reads its first batch of malpractice leads as poor quality. Often they are exactly as described and simply subject to a filter that happens downstream. The sequence a malpractice claim actually moves through, including prelitigation review and expert certification, is worth reading once even if your state runs it differently, because it shows how much has to happen before anyone knows what they have.

The cost that sits in the middle

Between the enquiry and the decision sits a stretch of work nobody bills for: requesting records, waiting for them, organising them, and having someone competent review them. In most states there is also a formal expert step before a case can be filed at all.

This is the part that makes the vertical different from every other one this blog has covered. Ordinary injury lead economics compare acquisition cost against signed cases. Here there is a third number in the middle, paid on cases that never sign, and a firm that has not measured it is flying on the wrong instrument.

It also explains a reaction that confuses suppliers. A firm asks for fewer, better leads and means it. In this vertical that is not a negotiating posture. Screening capacity is finite and expensive, and a firm that cannot review what it already has gains nothing from more.

What to ask for instead of volume

Write down what your reviewers will actually take

Not "serious cases". The specifics: which care settings, which categories of injury, what damages threshold makes review worth it for you, and which fact patterns you decline on sight regardless of merit. Firms that skip this end up arguing with suppliers in adjectives, which is the same failure this blog has described in other lead types and is worse here because the stakes per lead are higher.

Ask for the timeline facts up front

When the care happened, when the person became aware something had gone wrong, and whether any claim has already been made. Malpractice deadlines run on rules that differ by state and often turn on discovery rather than on the date of treatment, which means a matter can be time barred long before it feels old to the claimant. Getting those dates at intake costs nothing and stops the most expensive kind of wasted review.

Ask whether the records are obtainable

A claimant who has already requested their own records, or who can identify every provider involved, is materially further along than one who cannot remember which hospital. This is a question almost nobody asks at the lead stage and it predicts how long the middle section takes.

Agree what a rejected lead means

Rejection criteria in this vertical must be about the intake facts, not about the eventual merits. No supplier can know whether an expert will certify a case. A supplier can know whether the caller was in the right state, inside the right window, describing the right care setting, and reachable. Hold them to the second list and not the first.

What to measure

Cost per signed case is the only number that settles anything, and in this vertical it has to include the screening spend on the cases you declined. A firm measuring cost per lead in medical malpractice is measuring the cheapest and least informative part of the process.

Two other numbers are worth keeping. How many leads reached records review, which tells you whether intake screening is doing its job. And how many that reached review went on to sign, which tells you whether your acquisition is pointed at the right kind of matter. If the first number is healthy and the second is poor, the problem is targeting rather than volume.

Where the firm's own marketing fits

Malpractice is a vertical where a firm's own content does unusually well over time, because the people searching are researching rather than reacting, and they research for weeks. That is the opposite of a motor vehicle claimant who decides inside a day. Building out genuine depth on the conditions and settings you take, organised properly rather than scattered, compounds in a way that paid acquisition does not. There is a reasonable primer on structuring practice area content so it supports itself rather than competing with itself.

None of that is a reason to stop buying. It is a reason to treat bought leads here as the faster half of a two speed strategy rather than as the whole of it, which is the same conclusion this blog reached about building versus buying generally, arrived at from a different direction.

The short version

Medical malpractice leads are not expensive because somebody is marking them up. They are expensive because the work of finding out whether a case exists is expensive, and somebody pays for it either way. A firm that budgets for the middle section, writes down what its reviewers will take, and measures cost per signed case rather than cost per lead will make this vertical work. A firm that asks for more volume will spend more and sign the same number.